Correlation of Visible-Residue Limits with Swab Results for Cleaning Validation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Correlation of Visible-Residue Limits with Swab Results for Cleaning Validation


Pharmaceutical Technology



Figure 2
Diode array scans were taken of two of the 75-μg API samples; one with the expected recovery and one with high recovery. The scans were not significantly different (see Figures 1b, 2b), indicating that the peaks were related, if not the same. A peak purity profile for the sample with the expected recovery indicated that the peak was pure. The peak purity scan for the sample with higher than expected recovery indicated that more than one species was present in the scan (see Figures 1c, 2c). Mass spectrometry (MS) and nuclear magnetic resonance analyses of the samples were inconclusive. The sample concentrations were too low for positive identification.


Figure 3
In portions of some samples, the data indicated that one metformin double bond rearranged to form a set of conjugated double bonds (see Figure 3). The conjugated double-bond system exhibits greater ultraviolet absorbance than metformin where the double bonds are not conjugated. This finding explains the inconsistent, high swab recoveries, the single HPLC peak, and the diode-array impure peak composition. The manufacturer and most literature sources cite the nonconjugated version as the chemical structure for metformin. But, at least one source (7) displayed the alternate structure in Figure 3 as the chemical structure of metformin, supporting the conclusion deduced from the available data.


The swab process.
Several compounds have been tested that degraded during recovery studies. The compounds were known to be susceptible to either by oxidation or hydrolysis. Metformin was the first example of a compound that demonstrated increased absorbance as a result of the cleaning process. Any chemical change during recovery studies will affect recovery results as well as swab assays taken after routine cleaning. The current study demonstrated the value of establishing the VRL along with swab recoveries for cleaning validation.

Conclusions

The correlation between swab assay results and visible-residue limits (VRLs) for cleaning validation was examined. A review of previously completed validation studies was inconclusive because swab results were much lower than the more-recently determined VRLs. A current cleaning-validation study evaluated both swab testing and VRLs. Unexpectedly, high swab results led to an investigation that showed the value of establishing the VRL in conjunction with swab recoveries for cleaning-validation programs.

Richard Forsyth* is an associate director in Global Clinical GMP Quality with Merck & Co., Inc., WP53C-307, West Point, PA 19486, tel. 215.652.7462, fax 215.652.7106,
Julia Roberts is a research chemist in Vaccine Pharmaceutical Research, Tara Lukievics is a global sourcing project leader in the Global Clinical Supplies Organization, and Vincent Van Nostrand is a research chemist in medicinal chemistry with Merck & Co., Inc.

*To whom all correspondence should be addressed.

Submitted: May 16, 2006. Accepted: May 25, 2006. Keywords: cleaning, validation, visible-residue limits

References

1. D.W. Mendenhall, "Cleaning Validation," Drug Develop. Indust. Pharm. 15 (13), 2105–2114 (1989).

2. US Food and Drug Administration, Guide to Inspection of Validation of Cleaning Processes (Rockville, MD, Office of Regulatory Affairs, 1993).

3. D.A. LeBlanc, "'Visually Clean' as a Sole Acceptance Criteria for Cleaning Validation Protocols," J. Pharm. Sci. and Technol. 56 (1) 31–36 (2002).

4. R.J. Forsyth, V. Van Nostrand, and G. Martin, "Visible Residue Limit for Cleaning Validation and its Potential Application in a Pharmaceutical Research Facility," Pharm. Technol. 28 (10), 58–72 (2004).

5. R.J. Forsyth and V. Van Nostrand, "The Use of Visible Residue Limit for Introduction of New Compounds in a Pharmaceutical Research Facility," Pharm. Technol. 29 (4), 134–140 (2005).

6. R.J. Forsyth and V. Van Nostrand, "Application of Visible Residue Limit for Cleaning Validation in a Pharmaceutical Manufacturing Facility," Pharm. Technol. 29 (10), 152–161 (2005).

7. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, http://www.nvbi.nlm.nih.gov/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here